Your session is about to expire
← Back to Search
RPC1063 for Multiple Sclerosis
Study Summary
This trial is testing a new drug to treat relapsing multiple sclerosis. The goal is to see if it is safe and effective.
- Multiple Sclerosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 1012 Patients • NCT02435992Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
RPC1063 is often given to patients for what reason?
"RPC1063 is the standard medication for treating sclerosis, but it can also help patients with multiple sclerosis, active secondary progressive multiple sclerosis, and carcinoma in situ."
Have other medical studies like this one been conducted in the past?
"RPC1063 has 11 ongoing clinical trials in 287 cities and 52 countries. The first trial was sponsored by Celgene and completed in 2015 after enrolling 2350 participants. Phase 3 of the trial resulted in drug approval. Since 2015, there have been a total of 16 RPC1063 trials."
Does RPC1063 have a long and successful clinical trial history?
"RPC1063 was first studied in 2015 at Local Institution - 554. There have been a total of 16 completed trials since the initial study. There are 11 studies ongoing, with a significant number taking place in Raleigh, North carolina."
Could you walk me through the dangers associated with RPC1063?
"RPC1063 has undergone multiple rounds of testing and has been found to be safe. It is estimated to be a 3 on a scale of 1 to 3."
What hope does this trial offer to patients?
"The primary outcome of this study is to evaluate Adverse events of special interest (AESIs) over a period of up to approximately 7 years. Secondary outcomes include The number of gadolinium-enhanced brain magnetic resonance imaging lesions at each visit, Time to onset of disability progression as defined by a sustained worsening in Expanded Disability Status Scale (EDSS) of 1.0 points or more from baseline, and Annualized relapse rate."
Does this research allow for patients that are elderly?
"The target patient population for this study are individuals that are over 18 but under 55 years old."
Does this research project have several testing facilities within the state?
"So far, 46 research sites have been recruited for this study, such as Raleigh Neurology Associates PA in Raleigh, Bhupesh Dihenia MD PA in Lubbock, and Axiom Clinical Research of Florida in Tampa."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger